Maddi Hebebrand, MC, Associate Editor

Johnson & Johnson's icotrokinra shows promising results in treating moderate plaque psoriasis, especially in challenging areas like the scalp and genitals.

Recent analysis reveals abrocitinib's long-term safety in atopic dermatitis, highlighting age-related risks and the importance of tailored dosing for older patients.

FDA accelerates AI integration by 2025, enhancing scientific reviews and modernizing regulatory processes for improved public health outcomes.

The Clinical Image Collection enhances dermatologic education by providing diverse images of skin conditions, promoting inclusivity and accurate diagnoses across all skin tones.

Roflumilast foam shows significant efficacy in treating scalp and body psoriasis, enhancing patient adherence and quality of life in a recent clinical trial.

Explore the hidden health risks of nail products and the urgent need for safety reforms in the nail salon industry for workers and customers alike.

Delgocitinib cream significantly enhances health-related quality of life for patients with chronic hand eczema, addressing both symptoms and psychosocial impacts.

MJH Life Sciences acquires NewBeauty, merging clinical expertise with consumer-driven wellness to redefine beauty and aesthetics media.

Peter Lio, MD, discusses innovative treatments for pediatric atopic dermatitis, including microbiome therapies and botanical options.

Explore the top headlines of the week including insights on the latest clinical trials, therapeutic updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Guselkumab shows high effectiveness and safety in treating moderate to severe plaque psoriasis, enhancing quality of life in real-world Korean patients.

Explore the urgent need for sustainability in dermatology, addressing its environmental impact and advocating for eco-friendly practices in health care.

Acoustic stimulation using infrasound and low-frequency sound enhances wound healing, promoting cellular activity and tissue repair in innovative, non-invasive ways.

New research reveals JAK inhibitors for atopic dermatitis do not increase cardiovascular or cancer risks compared to IL-4/-13 inhibitors, offering reassurance for patients.

Explore the top headlines of the week including insights on recalls, expert pearls, and more.

The FDA approved pz-cel, a groundbreaking gene therapy for recessive dystrophic epidermolysis bullosa, transforming treatment options for patients.

JAK inhibitors show promise in treating alopecia areata among Black patients, highlighting the need for inclusive clinical research and equitable access to therapies.

Discover cutting-edge insights on atopic dermatitis at RAD 2025, featuring expert discussions and the latest therapies to enhance your practice.

Explore the top headlines of the week including insights on the latest clinical trials, therapeutic updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Explore the effectiveness of basic emollients in treating xerosis cutis associated with atopic dermatitis, enhancing skin hydration and barrier function.

Discover innovative rosacea treatments combining injectable hyaluronic acid with traditional therapies to enhance skin health and boost patient confidence.

Discover how upadacitinib outperforms dupilumab in providing rapid itch relief for moderate-to-severe atopic dermatitis in a recent AAD study.

Explore how tyrosine kinase inhibitors hinder wound healing, revealing critical insights for clinicians in dermatology and oncology.

Complete remission was achieved in over 87% of dupilumab users and 64% of omalizumab users.

Despite early psychological symptoms, over half of patients in the study completed their full treatment course.

Continuity with a known physician and rapid response times significantly increased patient willingness to use teledermatology.